High-Frequency QRS for Predicting Microvascular Dysfunction and Adverse Events After PCI in Acute Myocardial Infarction

High-Frequency QRS for Predicting Microvascular Dysfunction and Adverse Events After PCI in Acute Myocardial Infarction: A Prospective, Multicenter Cohort Study

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07138638

Enrollment

1112

Registered

2025-08-24

Start date

2025-08-31

Completion date

2027-12-31

Last updated

2025-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AMI

Keywords

Acute Myocardial Infarction, High-Frequency QRS, prediction model, Microvascular Dysfunction

Brief summary

This observational study aimed to investigate the prognostic value of high-frequency QRS (HF-QRS) in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI), as well as its potential role in diagnosing microvascular dysfunction. The main question it aims to answer is: 1. Whether HF-QRS could serve as an effective tool for early identification of high-risk AMI patients and prognosis prediction; 2. Whether HF-QRS provides auxiliary diagnostic value for post-AMI microvascular dysfunction. Participants underwent HF-QRS assessment and were prospectively followed for 1 year to record the incidence of major adverse cardiovascular events (MACE).

Interventions

DEVICEHigh-Frequency QRS

All enrolled patients underwent HF-QRS assessment, with subsequent recording of MACE to evaluate the predictive value of HF-QRS parameters for clinical outcomes

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Aged 18 to 75 years (inclusive) Diagnosed with acute myocardial infarction (AMI, including STEMI and NSTEMI) and underwent successful emergency PCI Voluntarily participated and provided written informed consent

Exclusion criteria

* History of prior myocardial infarction or chronic heart failure QRS duration \>120 ms (including paced rhythm, WPW syndrome, bundle branch block, or left ventricular hypertrophy with repolarization abnormalities) Structural heart disease (congenital heart disease, cardiomyopathy, aortic dissection, etc.) Persistent atrial fibrillation or malignant arrhythmias History of cerebral hemorrhage or ischemic stroke within 1 month Prolonged cardiopulmonary resuscitation or requiring advanced life support (IABP/ECMO, etc.) Scheduled for imminent surgery with anticipated inability to complete HF-QRS assessment Other life-threatening conditions including: Severe hepatic or renal dysfunction;Uncontrolled systemic diseases;Hematologic disorders;Active infections;Malignancy with life expectancy \<1 year Other investigator-determined exclusionary conditions:Pregnancy;Concurrent participation in other clinical trials Refusal to participate in the clinical study

Design outcomes

Primary

Measure	Time frame
To evaluate the predictive value of high-frequency QRS (HF-QRS) parameters for major adverse cardiovascular events (MACE) within 1 year after PCI in AMI patients and to construct a prognostic risk prediction model.	12 months

Secondary

Measure	Time frame
To evaluate the adjunctive diagnostic value of high-frequency QRS parameters for microvascular dysfunction in ACS patients following percutaneous coronary intervention	12 months

Countries

China

Contacts

Primary ContactYuan Lu, Ph.D

405983931@qq.com13952110901

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026